SCHEMBL7089130

SCHEMBL7089130

O=S(=O)(Nc1ccc2cccc(Br)c2n1)c1cccnc1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC40A1 Q9NP59 9/20 0.57
GLO1 Q04760 2/20 0.57
KMT2A Q03164 4/20 0.43
CA2 P00918 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TDP1 Q9NUW8 2/20 0.42
MEN1 O00255 2/20 0.42
G6PD P11413 1/20 0.42
NFKBIA P25963 1/20 0.42
AGTR1 P30556 1/20 0.42
METAP2 P50579 1/20 0.42
METAP1 P53582 1/20 0.42
PAX8 Q06710 1/20 0.42
ATM Q13315 1/20 0.42
KEAP1 Q14145 1/20 0.41
NFE2L2 Q16236 1/20 0.41
CKS1B P61024 3/20 0.40
SKP2 Q13309 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3071874 0.81 SLC40A1 (0.47) SLC40A1GLO1KMT2ACA2SMN1; SMN2
SCHEMBL7083753 0.80 ALDH1A1 (0.48) SLC40A1KMT2ATDP1MEN1
SCHEMBL3072255 0.79 SLC40A1 (0.59) SLC40A1GLO1KMT2ACA2SMN1; SMN2
SCHEMBL18423255 0.76 KMT2A (0.60) SLC40A1GLO1KMT2ACA2SMN1; SMN2
SCHEMBL15228476 0.74 PIM1 (0.48) KMT2ASMN1; SMN2TDP1MEN1
SCHEMBL30925462 0.73 SLC40A1 (1.00) SLC40A1GLO1KMT2ATDP1MEN1
SCHEMBL11973652 0.73 SLC40A1 (1.00) SLC40A1GLO1KMT2ATDP1MEN1
SCHEMBL1702487 0.71 KMT2A (0.47) SLC40A1KMT2ASMN1; SMN2TDP1MEN1
SCHEMBL27680502 0.71 POLB (0.46) SLC40A1GLO1KMT2AKEAP1NFE2L2
SCHEMBL6811801 0.70 SLC40A1 (0.56) SLC40A1GLO1KMT2ACA2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030144507-A1 Sulfonamide-containing heterocyclic compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2003-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144507-A1 Sulfonamide-containing heterocyclic compounds SLC5A2, SLC5A1, CBR3 SLC40A1 2821/4885GLO1 652/4885KMT2A 1187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.